Invasive aspergillosis in patients with hematologic malignancies: incidence and description of 127 cases enrolled in a single institution prospective survey from 2004 to 2009

Abstract

BackgroundThe study objectives were: 1) to report on invasive aspergillosis patients in a hematology department; and 2) to estimate its incidence according to the hematologic diagnosis. Design and MethodsA prospective survey of invasive aspergillosis cases was undertaken between January 2004 and December 2009 in the hematology department of a university hospital. Meetings with clinicians, mycologists and infection control practitioners were organized monthly to confirm suspected aspergillosis cases. Demographic characteristics, clinical and complementary examination results were recorded prospectively. Information on hospitalization was extracted from administrative databases. Invasive aspergillosis diagnosis followed the European Organization for Research and Treatment of Cancer criteria, and proven and probable IA cases were retained. A descriptive analysis was conducted with temporal trends of invasive aspergillosis incidence assessed by adjusted Poisson regression. ResultsOverall, 4,073 hospitalized patients (78,360 patient-days) were included in the study. In total, 127 (3.1%) patients presented invasive aspergillosis. The overall incidence was 1.6 per 1,000 patient-days (95% confidence interval: 1.4, 1.9) with a decrease of 16% per year (-1%, -28%). The incidence was 1.9 per 1,000 patient-days (1.5, 2.3) in acute myeloid leukemia patients with a decrease of 20% per year (-6%, -36%). Serum Aspergillus antigen was detected in 89 (71%) patients; 29 (23%) had positive cultures, and 118 (93%), abnormal lung CT scans. One-month mortality was 13%; 3-month mortality was 42%. Mortality tended to decrease between 2004 and 2009. ConclusionsInvasive aspergillosis incidence and mortality declined between 2004 and 2009. Knowledge of invasive aspergillosis characteristics and its clinical course should help to improve the management of these patients with severe disease.Key words: invasive aspergillosis, surveillance, hematologic disease, incidence, hospital. 2004 . Haematologica 2011 96(11):1685-1691. doi:10.3324/haematol.2011 Citation: Nicolle M-C, Bénet T, Thiebaut A, Bienvenu A-L, Voirin N, Duclos A, Sobh M, Cannas G, Thomas X, Nicolini F-E, De Monbrison F, Piens M-A, Picot S, Michallet M, and Vanhems P. Invasive aspergillosis in patients with hematologic malignancies: incidence and description of 127 cases enrolled in a single institution prospective survey from

Phase II Study on Voriconazole for Treatment of Chinese Patients with Malignant Hematological Disorders and Invasive Aspergillosis

“…In high-risk patients, the mortality rate of aspergillosis disease is reported to reach as high as 80% (Nicolle et al, 2011). However, conventional treatment in this setting is unsatisfactory, eg., itraconazole is low in its bioavailability and further could induce drug resistance, amphotericin B is associated with severe adverse reactions (Miller et al, 2011).…”

Invasive orbital aspergillosis in an apparently immunocompetent host without evidence of sinusitis

“…3 The lacrimal gland not only protects the ocular surface via a tear film, but also supplies the ocular surface with protective immu- (1.3%). 10 In comparison, the incidence of invasive aspergillosis among patients with NHL was 0.8% in one series. 11 While once not considered an at risk population, the incidence of invasive aspergillosis among those with aggressive NHL and multiple myeloma has increased over time due to the use of intensive chemotherapy.…”

“…1 The incidence of invasive aspergillosis in patients with hematologic malignancies has been reported to be as high as 3.1%, with A. fumigatus representing the most commonly isolated species. 10,11 The incidence of invasive aspergillosis is highest among patients with acute myeloid leukemia (1.9%), followed by those with acute lymphoblastic leukemia …”

Treatment of an Elderly Patient with Acute Myeloid Leukemia and Invasive Pulmonary Aspergillosis Infection with Combined Allogeneic Hematopoietic Stem Cells Microtransplantation and Voriconazole

“…The probability of invasive aspergillosis infection (IF) in patients with hematologic malignancies is 3.1 %, and the 90-day mortality rate is as high as 42 % [1]. Prognoses mainly depend on the state of the disease and the duration of neutropenia.…”